Ann Intern Med: 阿司匹林作为一级预防的出血风险

2016-04-17 MedSci MedSci原创

背景:阿司匹林相关的风险和利益之间的平衡,是应用阿司匹林作为一级预防关键点。目的:常规应用阿司匹林作为心血管疾病一级预防,评估严重出血的发生。数据源:PubMed、Medline、Cochrane对照试验登记(2010至20151月6)及其它相关文献回顾。研究的选择:随机对照试验;队列研究;和比较阿司匹林与安慰剂或不治疗预防成人心血管疾病或癌症荟萃分析。数据提取:一个研究人员选取数据,另一个研究人

背景:阿司匹林相关的风险和利益之间的平衡,是应用阿司匹林作为一级预防关键点。

目的:常规应用阿司匹林作为心血管疾病一级预防,评估严重出血的发生。

数据源:PubMed、Medline、Cochrane对照试验登记(2010至20151月6)及其它相关文献回顾。

研究的选择:随机对照试验;队列研究;和比较阿司匹林与安慰剂或不治疗预防成人心血管疾病或癌症荟萃分析。

数据提取:一个研究人员选取数据,另一个研究人员检查的准确性,和2个评估研究质量。

数据分析:在CVD一级预防的研究中,使用非常低剂量阿司匹林(≤100毫克每日或隔日)胃肠道(GI)严重出血风险增加58%(OR,1.58 95% CI,1.29 -1.95 ),出血性卒中风险增加27%(OR,1.27 95%CI,0.96-1.68 )。估计应用阿司匹林的出血事件取决于基线假设。应用基于社区观察样本基线出血率,估计应用阿司匹林严重出血事件,消化道出血为1.39(CI,0.70-2.28),出血性卒中为0.32(CI,-0.05 0.82)每1000人。这些事件在老年人,男性和存在心血管疾病危险因素人,出血事件增加,出血风险更高。

局限性:检测出血性卒中的效力是有限的。未检查其他严重出血的危害。

结论:基于对应用阿司匹林作为一级预防安全性的考虑,需要个体化评估阿司匹林对出血风险的影响,并调查因患者不同,绝对出血风险可能变化的获益。

原文出处:

Whitlock EP, Burda BU, et al. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Apr 12.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-10-06 1e10c84am36(暂无匿称)

    文章真心很好,感谢作者

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-05-10 QQ6709219e

    医学中的天平如何调,个体化

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-26 黑心天使

    个体化医疗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-19 李继凯

    文章不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=141008, encodeId=a96d141008ed, content=文章真心很好,感谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Oct 06 13:58:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85240, encodeId=3925852402f, content=医学中的天平如何调,个体化, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=172d1721528, createdName=QQ6709219e, createdTime=Tue May 10 11:03:00 CST 2016, time=2016-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82954, encodeId=c81d82954f1, content=个体化医疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Tue Apr 26 23:40:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606899, encodeId=0523160689969, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Apr 19 11:34:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79503, encodeId=14f0e9503b0, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79504, encodeId=c5cee9504f8, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 01:23:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-19 李继凯

    值得学习

    0

相关资讯

JAMA:PCI术后1年,还需要继续双抗血小板治疗吗?

经皮冠状动脉介入术(PCI)后进行双重抗血小板治疗可减少缺血性风险,但会增加出血风险。研究者进行了一项试验,建立一个临床决策工具,以识别PCI术后1年持续使用噻吩并吡啶类抗血小板药物的优劣。该研究纳入了11个国家的11 648名患者(DAPT 研究),根据PCI术后12-30个月的缺血和出血风险建立预测规则,再经过8136名患者进行验证(PROTECT)。先进行长达12个月的噻吩并吡啶+阿司匹林治

AIM:阿司匹林可预防心血管疾病和大肠癌,但究竟有无其他危害?

有证据表明,阿司匹林是预防心血管疾病(CVD)和结肠直肠癌(CRC)有效的一级药物,但是却增加了胃肠(GI)和脑出血的风险。原始出处:Steven P. Dehmer,Michael V. Maciosek,Thomas J. Flottemesch,et al.Aspirin for the Primary Prevention of Cardiovascular Disease and Col

Ann Intern Med:阿司匹林可作为心血管疾病的一级预防

背景:在美国,心血管疾病是导致死亡的主要原因。目的:对40岁或以上的成年人,阿司匹林预防心血管事件的益处进行系统的回顾,并对亚群的进行效应修饰评估。数据源: Medline、PubMed、Cochrane对照试验登记(2008年1月至2015年1月),和Cochrane系统评价数据库。研究的选择:根据预先设定的标准两位研究者独立分析了3396篇摘要,65篇文章。包括评价阿司匹林对心血管事件的一级预

Obstet Gynecol:备孕期间可以服用低剂量阿司匹林吗?

近期发表在Obstetrics and Gynecology的研究称,受孕前服用低剂量阿司匹林,无论是对孕妇还是胎儿都具有良好的耐受性,不过研究也指出,罕见和严重的并发症无法排除。众所周知低剂量阿司匹林不仅对先兆子痫有益,对妊娠结局也会有潜在的益处。那么孕前使用低剂量阿司匹林,会不会对母婴有什么影响呢?研究者对阿司匹林对妊娠和生殖影响试验的数据进行了二次分析。该研究为多中心、随机、双盲、安慰剂对照

Hepatology:阿司匹林可降低胆管癌风险

阿司匹林能预防胆管癌(CCA)吗?研究者对CCA患者进行了一项基于医院的病例对照研究,探究阿司匹林对CCA的影响,以及不同CCA类型的危险因素。研究共纳入了2000-2014年梅约诊所的2395名CCA患者,其中1169名为肝内CCA患者,995名为肝门部CCA患者,231名为远端CCA患者。根据年龄、性别、种族和居住地按2:1匹配了4769名对照组。CCA组和对照组分别为591 (24.7%)名

JAMA Oncol:常规性地使用阿司匹林能够帮助降低癌症发病风险

(图片摘自www.sciencealert.com)长久以来,阿司匹林被认为对人类健康有许多益处。如今,一项最近的研究认为这一药物能够有效降低人们患癌症的风险。根据哈佛大学研究者们的研究结果,长期服用阿司匹林能够降低3%的癌症发病风险,其中主要包括结肠癌与其它癌症类型。虽然科学家们之前已经知道阿司匹林对这些特定癌症类型具有一定的疗效,但这还是首次发现其也能帮助降低癌症的发病风险。科学家们首先利用美